The incidence of Metabolic Syndrome in Subclinical Hypothyroid patients

Year 2019, , 47 - 53, 28.08.2019

Harun Düğeroğlu

https://doi.org/10.19127/mbsjohs.561137

Abstract

Objevtive: The aim of this study was to evaluate
the incidence of metabolic syndrome, a risk factor for chronic diseases such as
cardiovascular diseases, diabetes mellitus and stroke, in patients with
subclinical hypothyroidism.

Methods: A total of 108 patients with
subclinical hypothyroidism followed in the outpatient clinic of Ordu University
Faculty of Medicine Training and Research Hospital between 2015-2018 were
included in the study. Height, waist circumference, weight, blood pressure, High
Density lipoprotein (HDL) cholesterol and triglyceride levels and fasting blood
glucose levels were recorded from the archive records of the patients. Body
Mass Index (BMI) was calculated. Metabolic Syndrome (MetS) diagnoses were made
according to the National Cholesterol Education Program Adult Treatment Panel
III (NCEP ATP III) guidelines.

Results: Of the 108
patients included in the study, 74 (68.5%) were female and 34 (31.5%) were
male. The mean age of the female patients was 38.3±12.5 years and the mean age
of the male patients was 40.5±11.7 years. In this study, the prevalence of MetS
was 42.6% (47.3% in females and 30.8% in males) in patients with subclinical
hypothyroidism. MetS incidence was 1.5 times higher in female patients than in
male patients. Among all patients, the most common MetS component was low HDL
cholesterol (54.6%) and abdominal obesity (52.8%).

Conclusion:
The incidence of MetS was higher in female patients with subclinical
hypothyroidism than in male patients. In addition, close follow-up of patients
with subclinical hypothyroidism in terms of Metabolic Syndrome, which is a risk
factor for many chronic diseases such as diabetes mellitus, cardiovascular
diseases and stroke, will benefit in reducing the mortality of patients.

Keywords

Subclinical hypothyroid, metabolic syndrome, incidence

References

• Akbulut G. Does the Prevalence of metabolic syndrome in pre- and post-menopausal women differ by the ATP III and IDF Criteria? Turkiye Klinikleri J Med Sci 2011;31(6):1463-70.
• Balkau B, Valensi P, Eschwe`ge E, Slamad G. A review of the metabolic syndrome. Diabetes Metab 2007;33:405–13.
• Baltali M, Kızıltan HT, Korkmaz ME, Topcu S, Demirtas M, Topcuoglu S, et al. Ko Metabolic syndrome in patients after coronary bypass surgery: Prevalence and compliance with treatment. Anatol J Cardiol 2004;4:10-16.
• Bengel FM, Lehnert J, Ibrahim T, Klein C, Bulow HP, Nekolla SG, et al. Cardiac oxidative metabolism, funtion and metabolic performance hypertiroidism: a noninvasive study using positron emission ton and magnetic resonance imaging, Thyroid 2003; 13: 471-7.
• Bloomgarden ZT. American Association of Clinical Endocrinologists (AACE) consensus conference on the insulin resistance syndrome:25-26 August 2002, Washington, DC. Diabetes Care 2003;26:1297-03.
• Demir D, Bucaktepe EG, Kara IH. The Comparing of the sociodemographic features, anthropometric and biochemical parameters of the cases with Metabolic Syndrome, Type 2 Diabetes Mellitus and healthy controls. Konuralp Medical Journal 2010;2(1):12-9.
• Fadeyev VV, Sytch J, Kalashnikov V, Rojtman A, Syrkin A, Melnichenko G. Levothyroxine replacement therapy in patients with subclinical hypothyroidism and coronary artery disease. Endocr Pract 2006; 12: 5-17.
• Foldes J, Banos C, Winkler G. Subclinical hypothyroidism and arteriosclerosis. Orv Hetil 2004; 145: 1601-7.
• Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA 2002;287:356–9.
• Grundy SM. Metabolic syndrome: connecting and reconcoling cardiovasculer and diabetes world. J Am Coll Cardiol 2006; 47: 1093-100.
• Gupta A, Gupta R, Sarna M, Rastogi S, Grupta VP, Kothari K. Prevalence of diabetes, impaired fasting glucose and insulin resistance syndrome in an urban Indian population. Diabetes Res Clin Pract 2003;61:69–76.
• Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, et al. 2002 Serum TSH, T4, and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002; 87: 489-99.
• Karakurt F, Carkoglu A, Koroglu M, Us B, Kasapoglu B. Is thyroid function a risk factor for obesity? Yeni Tıp Dergisi 2009; 26:27-30.
• Kitis Y, Bilgili N, Hisar F, Ayaz S. Frequency and affecting factors of metabolic syndrome in women older than 20 years of age. Anadolu Kardiyol Derg 2010;10:111-9.
• Kllein I. Thyroid hormone and high blood pressure. In; Laragh JH, Brenner BM. Kaplan NM, editors. Endocrine mechasnism in hyper tension, 2nd ed. New York: Raven Pres; 1989. p.61-80.
• Kozan O, Oguz A, Abaci A, Erol C, Ongen Z, Temizhan A, et al. Prevalence of the metabolic syndrome among Turkish adults (METSAR). Eur J Clin Nutr 2007; 61:548-53.
• Lonn L, Stenlof K, Ottoson M, Lindoors AK, Mystrom E, Sjosstrom L. Body weight and body composition changes after treatment of hypothyroidism, Journal of Clinical Endocrinology and Metabolism 1998; 83: 4269-73.
• Misra A, Khurana L. The metabolic syndrome in South Asians: epidemiology, determinants, and prevention. Metab Syndr Relat Disord 2009;7(6):497-14.
• Miyatake N, Kawasaki Y, Nishikawa H, Takenami S, Numata T. Prevalence of metabolic syndrome in Okayama prefecture, Japan. Intern Med. 2006;45(2):107-8.
• Monzani F, Dardano A, Caraccio N. Does treating subclinical hypothyroidism improve markers of cardiovascular risk? Treat Endocrinol 2006; 5: 65-81.
• Morkin E, Flink IL, Goldman S. Biochemical and physiologic effects of thyroid hormone on cardiac performance. Prog Cardiovace Dis 1983; 25: 435-64.
• National Cholesterol Education Program (NCEP) Expert Panel on Detection. Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3121–43.
• Oguz A, Metabolic Syndrome, Ed. Ozata M, Yonem A, Endocrinology Metabolism and Diabetes. 1. baskı. Istanbul: Istanbul Medical pub; 2006:550-65.
• Onat A, Ceyhan K, Basar O, Erer B, Toprak S, Sansoy V. Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels: prospective and cross-sectional evaluation. Atherosclerosis 2002;165:285-92.
• Onat A, Sansoy V. Metabolic Syndrome, Major Culprit of Coronary Disease Among Turks: Its Prevalence and Impact on Coronary Risk. Turk Kardiyol Dern Ars. 2002; 30(1): 8-15
• Parle JV, Franklyn JA, Cross KW, Jones SC, Sheppard MC. Prevalence and follow-up of abnormal thyrotrophin (TSH) concentrations in the elderly in the United Kingdom. Clin Endocrinol (Oxf) 1991; 34: 77-83.
• Reaven GM. Banting Lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988; 37: 1595-607.
• Rennie KL, McCarthy N, Yazdgerdi S, Marnot M, Brunner E. Association of the metabolic syndrome with both vigorous and moderate physical activity. Int J Epidemiol 2003; 32: 600-6.
• Roos A, Bakker SJ, Links TP, Gans RO, Wolffenbuttel BH. Thyroid function is associated with components of the metabolic syndrome in euthyroid subjects. J Clin Endocrinol Metab 2007; 92: 491-6.
• Shantha GP, Kumar AA, Jeyachandran V, Rajamanickam D, Rajkumar K, Salim S, et al. Association between primary hypothyroidism and metabolic syndrome and the role of C reactive protein: a cross-sectional study from South India. Thyroid Res 2009; 2: 2.
• Tagliaferi M, Berselli ME, Calo G, Minocci A, Savia G. Petroni ML, et al. Subclinical hypotroidism in obese patients: relation to resting energy expanditute serum leptin body compasition and lipid profile. Obes Res 2001; 9: 196-201.
• Takashima N, Mannami T, Tomoike H, Iwai N. Characterization of subclinical thyroid dysfunction from cardiovascular and metabolic viewpoints: the Suita study. Circ J 2007; 71: 191-5.
• Tamer I, Sargin M, Sargin H, Seker M, Babalik E, Tekce M, et al. The evaluation of left ventricular hypertrophy in hypertensive patients with subclinical hyperthyroidism. Endocr J 2005; 52:421-5.
• Varlıbas F, Gencer M, Orken C, Cakal N, Tireli H. Metabolic syndrome in cerebrovascular diseases. Journal of Neurological Science 2006;23 (2):93-101. Villar HC, Saconato H, Valante O, Atallah AN. Thyroid hormone replacement for subclinical hypothyroidism. Cochrane Database Syst Rev 2007: CD 003419.
• World Health Organization. Prevention and management of the global epidemic of obesity. Report of the WHO Consultation on Obesity. Geneva: WHO; 1998 (Technical Report Series, No. 894).